In a Phase IIb, dose-finding, randomised, placebo-controlled trial (SYNERGY-NASH) involving 190 participants with obesity and biopsy-confirmed MASH and stage F2 or F3 fibrosis, once-weekly subcutaneous tirzepatide (5 mg, 10 mg or 15 mg for 52 weeks) resulted in significantly higher rates of MASH resolution without worsening of fibrosis (44%, 56% and 62%, respectively) than placebo (10%)
(The Financial Times has an excellent story on the scientific and economic race to make these new pills
Contrave helps control cravings and reduce hunger
Make sure your body is getting all the nutrition it needs to stay healthy and keep you strong
Zhang S., Holmes T., Lockshin C., Rich A
The company also points out that no NCAA athlete has been declared ineligible due to consuming Celsius, according to celcius.com